Education
About Us
Working with TipRanks
Follow Us
Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
COYA Stock Chart & Stats
$6.47
-$0.10(-1.62%)
At close: 4:00 PM EST
$6.47
-$0.10(-1.62%)
Day’s Range― - ―
52-Week Range$4.65 - $10.24
Previous CloseN/A
Volume16.99K
Average Volume (3M)128.96K
Market Cap
N/A
Enterprise Value$66.41M
Total Cash (Recent Filing)$29.76B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 05, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding16,725,080
10 Day Avg. Volume219,113
30 Day Avg. Volume128,957
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)2.21
Price to Sales (P/S)24.57
P/FCF Ratio-8.49
Enterprise Value/Market Cap10.00T>
Enterprise Value/Revenue156.83
Enterprise Value/Gross Profit164.82
Enterprise Value/Ebitda-0.01
Forecast
1Y Price Target
$17.25Price Target Upside166.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial StabilityCoya Therapeutics ended 2Q25 with $29.8M in cash and cash equivalents, which along with the expected milestone payments from DRL should be sufficient to fund operations into at least 2H26 based on forecasts.
Regulatory ProgressThe ALS trial agreement with the agency on testing two immune-modulators shows regulatory progress and potential effectiveness in treating inflammatory diseases.
Research CommitmentThe company has nearly doubled the cohort for its open label study, indicating increasing interest and commitment to the research.
Bears Say
Clinical RisksRisks include clinical setbacks involving COYA 302 in ALS and/or AD, and failure to secure U.S. regulatory approval.
Medium-term RisksRisks include clinical setbacks involving COYA 302 in ALS and/or AD, failure to secure U.S. regulatory approval, and possible medium-term dilution risk.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $4.65 and its highest was $10.24 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 13 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.419 by $0.059.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 16,725,080 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.419. Following the earnings report the stock price went down -0.325%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
COYA Stock 12 Month Forecast
Average Price Target
$17.25
▲(166.62% Upside)
Technical Analysis
Ownership Overview
6.19% Insiders
5.88% Mutual Funds
18.58% Other Institutional Investors
64.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---